Product Description
The Global MIS Sacroiliac Joint Fusion Market was valued at nearly $330 million In 2024. This is expected to increase over the forecast period at a CAGR of 8.8% to reach $595 million.
The full report suite on the global market for minimally invasive sacroiliac (MIS SI) joint fusion includes market analysis complete with units sold, ASPs and market value.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2031, and Historical Data to 2024
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
GLOBAL SACROILIAC JOINT FUSION MARKET TRENDS
A major driver of the MIS SI joint fusion market is the growing recognition of sacroiliac joint dysfunction as a significant source of lower back pain. MIS techniques are gaining popularity among patients and surgeons alike due to their advantages over open fusion procedures, including faster recovery times, reduced blood loss and lower complication rates.
GLOBAL SACROILIAC JOINT FUSION MARKET SHARE INSIGHTS
- SI-BONE was the leading competitor in the global MIS SI Joint fusion market in 2024 . SI-BONE was the first company to enter the MIS SI fusion market space with its iFuse Implant System® (iFuse®). It held around half of the total market share in all regions, giving it a substantial lead in the global MIS SI joint fusion space.
- Medtronic was the second-leading competitor in the global MIS SI joint fusion market in 2024. Its primary product in this segment was the ANCHOR FS™. Regionally, Medtronic ranked second in North America but held the second-leading position in both Western Europe and the Rest of the World.
- Globus Medical/NuVasive was the third-leading competitor in the global MIS SI joint fusion market in 2024. Its primary product in this segment was ZYFUSE®. Regionally, Globus Medical/NuVasive ranked fourth in North America and third in both Western Europe and the Rest of the World.
RESEARCH SCOPE SUMMARY
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Baltic States, Bulgaria, Kazakhstan, Poland, Romania, Croatia, Czech Republic, Russia, Greece, Turkey, Hungary, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Vietnam) Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2023 |
| Forecast Period | 2025-2031 |
| Historical Data | 2021-2023 |
| Quantitative Data | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Data | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
